

output node), or that the training set should include over 30 000 cases.

The aim in training a classification ANN is to extract features from the training data that characterise the classes of interest. Since Zou *et al*'s ANN has well over 15 000 path options for the training set of 60 cases, the feature extraction properties of the ANN were redundant. The ANN was simply required to represent each training case in learning space. Classification of the test data would have proceeded by finding the closest match among the training data representations and adopting this diagnosis. Zou *et al*'s approach has, therefore, probably created a pattern matching system rather than a true ANN classification system. As such, it achieved a satisfactory result, but would be expected to be less successful when more diagnostic groups are added and the classification task is more complex.

ANNs have considerable promise in the classification of psychiatric disorders (Galletly *et al*, 1996). However, an ANN is not merely a black box. Attention must be given to the choice of appropriate architecture, input data, training and test data sets, classification thresholds and initial weights, all of which appear to be either less than optimal or unspecified in Zou *et al*'s paper.

GALLETLY, C., CLARK, C. & MCFARLANE, A. (1996) Artificial neural networks: A prospective tool for the analysis of psychiatric disorders. *Journal of Psychiatry and Neuroscience*, **21**, 239–247.

ZOU, Y., SHEN, Y., SHU, L., *et al* (1996) Artificial neural network to assist psychiatric diagnosis. *British Journal of Psychiatry*, **169**, 64–67.

C. A. GALLETLY
C. R. CLARK

*Cognitive Neuroscience Laboratory and School of Psychology
Flinders University of South Australia
GPO Box 2100
Adelaide, SA 5001*

A. C. MCFARLANE

*Department of Rehabilitation and Community Psychiatry
University of Adelaide
South Australia*

Lithium and ECT in combination

SIR: We read with interest the article by Jha *et al* (1996). The clinical implication suggested by the authors, "The combination of ECT and lithium may be justified in selected cases" needs to be viewed with caution. There are some reports to

suggest increased risk of neurotoxicity associated with ECT and lithium in combination (Small *et al*, 1980; El-Mallakh, 1988). Potential risk of prolongation of depolarising muscle relaxant effects by lithium is possible (Hill *et al*, 1976). In any case, there are no confirmed trials showing therapeutic advantage of ECT and lithium in combination over ECT sans lithium.

It is therefore clinically prudent to withhold lithium during ECT. Lithium may be restarted, if indicated, after completion of a course of ECT. In our experience, such a strategy has not resulted in any symptom relapse during the period before therapeutic levels are achieved.

EL-MALLAKH, R. S. (1988) Complications of concurrent lithium and electroconvulsive therapy: A review of clinical material and theoretical considerations. *Biological Psychiatry*, **23**, 595–601.

HILL, G. E., WONG, K. G. & HODGES, M. R. (1976) Potentiation of succinylcholine neuromuscular blockade by lithium carbonate. *Anesthesiology*, **44**, 439–441.

JHA, A. K., STEIN, G. S. & FENWICK, P. (1996) Negative interaction between lithium and electroconvulsive therapy – A case-control study. *British Journal of Psychiatry*, **168**, 241–243.

SMALL, J. G., KELLAMS, J. J., MILSTEIN, V., *et al* (1980) Complications with electroconvulsive treatment combined with lithium. *Biological Psychiatry*, **15**, 103–112.

B. N. GANGADHAR
N. JANAKIRAMAIAH

*Department of Psychiatry
National Institute of Mental Health and Neurosciences
Bangalore 560 029
India*

False memory syndrome

SIR: I wish to clarify a comment about the False Memory Syndrome Foundation made by Brewin in his editorial (1996). He states:

"Recently, however, doubt has been cast on the process whereby forgotten memories of child sexual abuse appear to be recovered within therapy, and it has been suggested that many if not all of these memories are the product of inappropriate therapeutic suggestion. This suggestion has been promulgated in particular by the False Memory Syndrome Foundation in the US. . ."

The False Memory Syndrome Foundation has no way of knowing whether or not "many" memories recovered in therapy are the product of inappropriate suggestion. Therapy sessions are confidential. There does, however, seem to be ample evidence that some memories recovered in therapy may be false. There is also evidence that some therapists practice techniques that carry a high risk of suggestion. Research by Poole *et al* (1994) indicates that

25% of PhD psychologists use techniques that increase the risk of memory suggestion.

We have noted that there is a distinction between the claims of recovery of a memory of a single event and the claims of recovery of many memories of hundreds of events extending over long periods of many years. The reports that have been received by the False Memory Syndrome Foundation generally include claims that a person has recovered many memories of numerous events that took place over many years after total amnesia for all these events. Such claims represent a new kind of phenomenon. In 1989 Briere introduced a new mental mechanism that he said was only recently discovered and causes patients to become completely amnesic and suffer the "complete loss of childhood sexual abuse memories" (p. 49). Extraordinary claims deserve extraordinary evidence. Without such evidence, such claims must be taken with scepticism.

The position of the Foundation has always been that whether they are continuous or recovered, some memories are true, some a mixture of fact and fantasy and some are false. The problem is to know the difference.

BRIERE, J. (1989) *Therapy for Adults Molested as Children: Beyond Survival*. New York: Springer.

BREWIN, C. R. Scientific status of recovered memories. *British Journal of Psychiatry*, **169**, 131–134.

POOLE, D., *et al* (1994) Psychotherapy and the recovery of memories of childhood sexual abuse: US and British practitioners' opinions, practices, and experience. *Journal of Consulting and Clinical Psychology*, **63**, 426–437.

FMS Foundation
Philadelphia, PA 19104
USA

P. FREYD,

neighbours. Cognition was globally impaired (Mini Mental State Examination 13/30). Physical examination revealed only impaired visual acuity. Investigations were normal. Sulpiride (100 mg per day) was commenced but the patient soon became drowsy and showed marked stiffness and cogwheeling. She became immobile, uncommunicative and doubly incontinent. The sulpiride was stopped and a diagnosis of "probable dementia with Lewy bodies" was made (International Workshop on Dementia with Lewy Bodies, 1996, in press). Procyclidine was commenced and gradually increased to 10 mg t.d.s. but rigidity steadily worsened. The patient was frightened, screaming at times, hardly ate and required intermittent intravenous hydration. Eleven weeks after stopping the sulpiride, baclofen was started and cautiously increased to 15 mg t.d.s. while procyclidine was reduced and stopped. (Baclofen may itself exacerbate psychosis and confusion.)

Two weeks later Mrs T. was much more settled, with no signs of distress. Her affect was reactive, while verbal communication and oral input improved markedly. Stiffness gradually resolved and mobility improved. In another patient with LBD we have again found that baclofen was far more effective than procyclidine in reducing stiffness. Baclofen may therefore be useful in the treatment of rigidity associated with diffuse Lewy body dementia, and merits further evaluation. (Acknowledgement: Thanks to Rodney Walker for his advice.)

INTERNATIONAL WORKSHOP ON DEMENTIA WITH LEWY BODIES (1996) Consensus criteria for the clinical diagnosis of dementia with Lewy bodies. *Neurology*, in press.

MCKEITH, I. G., FAIRBAIRN, A., PERRY, R., *et al* (1992) Neuroleptic sensitivity in patients with senile dementia of Lewy body type. *British Medical Journal*, **305**, 673–678.

M. MOUTOUSSIS

Department of Psychiatry
Princes Alexandra Hospital
Harlow CM20 1QX

W. ORRELL

University College London Medical School
Middlesex Hospital
London WIN 8AA

Baclofen therapy for rigidity associated with Lewy body dementia

SIR: Lewy body dementia (LBD) often shows a marked sensitivity to neuroleptics (McKeith *et al*, 1992). Anticholinergic agents used to treat extrapyramidal side-effects of these drugs are often unsuccessful in LBD and can exacerbate confusion and psychosis. We report a case of LBD with severe extrapyramidal rigidity who responded well to treatment with baclofen, a γ -aminobutyric acid agonist.

Mrs T., a 90-year-old widow, was admitted with a two-year history of memory loss. Distressing visual hallucinations included "a baby monkey with a long tail". She had become disoriented and repeatedly and inappropriately telephoned her

An atypical case of parasuicide or 'bradysuicide'

SIR: The term parasuicide refers to a non-fatal deliberate act of self-injury or ingestion of substances in excess of normally used doses.

A 35-year-old kindergarten teacher, who had a past history of sedative overdose, became depressed upon her father's death and decided to end her life